

Bibliography and Suggested Reading

Navigating Novel Terrain in Vitiligo Management: A Practical, Patient-Centric Review

Aboul-Fettouh N, et al. The majority of patients presenting with vitiligo have a clinical sign of activity. *J Am Acad Dermatol*. 2017;77(4):774-775.

Alikhan A. Vitiligo: A comprehensive overview: Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology and work-up. *J Am Acad Dermatol*. 2011;65(3):473-491.

AL-smadi K, Imran M, Leite-Silva VR, et al. Vitiligo: a review of aetiology, pathogenesis, treatment, and psychosocial impact. *Cosmetics*. 2023; 10(3):84.

Baidya S, Dey P, Mohanty R. Assessment of quality of life in vitiligo patients attending a tertiary care hospital - A cross sectional study. *Ind Psychiatry J*. 2021;30(1):62-66.

Bergqvist C, Ezzedine K. Vitiligo: a review. *Dermatology*. 2020;236(6):571-592.

Bertolani M, Rodighiero E, de Felici Del Giudice MB, et al. Vitiligo: what's old, what's new. *Dermatol Reports*. 2021;13(2):9142.

Bibeau K, Ezzedine K, Harris JE, et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. *JAMA Dermatol*. Published online August 30, 2023.

Bukhari AE. New-onset of vitiligo in a child following COVID-19 vaccination. *JAAD Case Rep*. 2022;22:68-69.

Cunningham KN, Rosmarin D. Vitiligo Treatments: Review of current therapeutic modalities and JAK inhibitors. *Am J Clin Dermatol*. 2023;24(2):165-186.

Delbaere L, Speeckaert R, Herbelet S, et al. Biomarkers and clinical indicators of disease activity in vitiligo. *Dermatological Reviews*. 2022;3:289-307.

Diotallevi F, Gioacchini H, De Simoni E, et al. Vitiligo, from pathogenesis to therapeutic advances: state of the art. *Int J Mol Sci*. 2023;24(5):4910.

Drugs@FDA: FDA-Approved Drugs. Ruxolitinib cream. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215309s001lbl.pdf. Accessed March 2024.

Bibliography and Suggested Reading

Navigating Novel Terrain in Vitiligo Management: A Practical, Patient-Centric Review

Ezzedine K, Ahmed M, Tovar-Garza A, et al. Cross-cultural validation of a short-form of the Vitiligo Impact Patient scale (VIPs). *J Am Acad Dermatol*. 2019;81(5):1107-1114.

Ezzedine K, Lim HW, Suzuki T, et al; Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. *Pigment Cell Melanoma Res*. 2012;25(3):E1-13.

Ezzedine K, Peeva E, Yamaguchi Y, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. *J Am Acad Dermatol*. 2023;88(2):395-403.

Ezzedine K, Sheth V, Rodrigues M, et al. Vitiligo is not a cosmetic disease. *J Am Acad Dermatol*. 2015;73(5):883-885.

Faraj S, Kemp EH, Gawkrödger DJ. Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors. *Clin Exp Immunol*. 2022;207(1):27-43.

Felsten K, Alikhan A, Petronic-Rosic V, et al. Vitiligo: A comprehensive overview: Part II: Treatment options and approach to treatment. *J Am Acad Dermatol*. 2011;65(3):493-514.

Gandhi K, Ezzedine K, Anastassopoulos KP, et al. Prevalence of vitiligo among adults in the United States. *JAMA Dermatol*. 2022;158(1):43-50.

Garza-Mayers AC, Paquette GM, Harris JE, et al. Narrowband ultraviolet B phototherapy in pediatric vitiligo: A retrospective study. *J Am Acad Dermatol*. 2023;89(1):135-136.

Jin Y, Roberts GHL, Ferrara TM, et al. Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression. *Nat Commun*. 2019;(1):391.

Kim JC, Kim DC, Kang HY, Kim DS. Treatment outcomes and prognostic factors of motorized 0.5-mm micropunch grafting with a skin-seeding technique for 83 cases of vitiligo in children. *J Am Acad Dermatol*. 2023;88(2):506-508.

Learned C, Cohen SR, Alsukait S, et al. Vitiligo adverse events and associated medications as reported in the US Food and Drug Administration's Adverse Event Reporting System from 2016 to 2021. *J Am Acad Dermatol*. 2023;88(1):197-199.

Lee JH, Kwon HS, Jung HM, et al. Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis. *JAMA Dermatol*. 2019;155(8):929-938.

Bibliography and Suggested Reading

Navigating Novel Terrain in Vitiligo Management: A Practical, Patient-Centric Review

Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. *Arch Dermatol*. 2003;139(5):581-585.

Lim JH, Lew BL, Sim WY, et al. Incidence of childhood-onset vitiligo and increased risk of atopic dermatitis, autoimmune diseases, and psoriasis: A nationwide population-based study. *J Am Acad Dermatol*. 2022;87(5):1196-1198.

Linthorst Homan MW, Spuls PI, de Korte J, et al. The burden of vitiligo: patient characteristics associated with quality of life. *J Am Acad Dermatol*. 2009;61(3):411-420.

Liu L, Yang Q, Su MW, et al. Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001). *JAAD Case Rep*. 2023;39:150-151.

Mohammad TF, Al-Jamal M, Hamzavi IH, et al. The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo. *J Am Acad Dermatol*. 2017;76(5):879-888.

Mumtaz H, Anis S, Akhtar A, et al. Efficacy of tacrolimus versus clobetasol in the treatment of vitiligo. *Cureus*. 2020;12(12):e11985.

Parsad D, Pandhi R, Dogra S, et al. Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. *J Am Acad Dermatol*. 2004;50(1):63-67.

Patra S, Khaitan BK, Sharma VK, et al. A randomized comparative study of the effect of betamethasone oral mini-pulse therapy versus oral azathioprine in progressive nonsegmental vitiligo. *J Am Acad Dermatol*. 2021;85(3):728-729.

Radakovic-Fijan S, Fürnsinn-Friedl AM, Hönigsmann H, et al. Oral dexamethasone pulse treatment for vitiligo. *J Am Acad Dermatol*. 2001;44(5):814-817.

Rodrigues M, Ezzedine K, Hamzavi I, et al; Vitiligo Working Group. Current and emerging treatments for vitiligo. *J Am Acad Dermatol*. 2017;77(1):17-29.

Rosmarin D, Passeron T, Pandya AG, et al; TRuE-V Study Group. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. *N Engl J Med*. 2022;387(16):1445-1455.

Schmidt AF, Rubin A, Milgraum D, et al. Vitiligo following COVID-19: A case report and review of pathophysiology. *JAAD Case Rep*. 2022;22:47-49.

Bibliography and Suggested Reading

Navigating Novel Terrain in Vitiligo Management: A Practical, Patient-Centric Review

Sheth VM, Guo Y, Qureshi AA. Comorbidities associated with vitiligo: a ten-year retrospective study. *Dermatology*. 2013;227(4):311-315.

Sosa JJ, Currimbhoy SD, Ukoha U, et al. Confetti-like depigmentation: A potential sign of rapidly progressing vitiligo. *J Am Acad Dermatol*. 2015;73(2):272-275.

Thawabteh AM, Jibreen A, Karaman D, et al. Skin pigmentation types, causes and treatment-a review. *Molecules*. 2023;28(12):4839.

Varma K, Kumar U, Mahadik A, et al. An observational study of Vitiligo. *IP Indian J Clin Exp Dermatol*. 2022;8(1):39-42.

Vallerand IA, Lewinson RT, Parsons LM, et al. Vitiligo and major depressive disorder: A bidirectional population-based cohort study. *J Am Acad Dermatol*. 2019;80(5):1371-1379.

Vitiligo Causes. American Academy of Dermatology. Available at: <https://www.aad.org/public/diseases/a-z/vitiligo-causes>. Accessed March 2024.

Zhang L, Chen S, Kang Y, et al. Association of clinical markers with disease progression in patients with vitiligo from China. *JAMA Dermatol*. 2020;156(3):288-295.